• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA OKs BioDelivery Sciences’ Bunavail opioid dependence film

May 2, 2017 By Sarah Faulkner

BioDelivery SciencesBioDelivery Sciences International (NSDQ:BDSI) said today that the FDA approved a supplemental new drug application for its Bunavail buprenorphine and naloxone buccal film. The revised indication allows patients to use the product to initiate buprenorphine treatment for opioid dependence.

Induction is the initial process by which a patient transitions from abusing an opioid to buprenorphine treatment which is designed to relieve cravings and withdrawal, according to BioDelivery Sciences.

The FDA approved Bunavail’s initial new drug application in June 2014, which covered the film for use during the maintenance treatment phase of opioid dependence therapy.

The Raleigh, N.C.-based company said the expanded indication will likely help maintain competitiveness in the market.

BioDelivery Sciences touts Bunavail as the 1st and only buprenorphine and naloxone formulation for administration inside of the cheek. The buccal film has twice the bioavailability of buprenorphine compared to the market leader, Suboxone, according to the company. BioDelivery Sciences said that Bunavail’s increased bioavailability means that plasma concentrations of buprenorphine comparable to Suboxone can be achieved with half the dose, reducing the potential for misuse.

BDSI shares were trading at $1.83 apiece in mid-morning activity today, up 4.3%

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: BioDelivery Sciences International

IN CASE YOU MISSED IT

  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS